Density of GFAP-immunoreactive Astrocytes is Decreased in Left Hippocampi in Major Depressive Disorder

Overview

Journal Neuroscience

Specialty Neurology

Date 2016 Jan 9

PMID 26742791

Citations 109

Authors

J A Cobb

K ONeill

J Milner

G J Mahajan

T J Lawrence

W L May

J Miguel-Hidalgo

G Rajkowska

C A Stockmeier

Affiliations

Soon will be listed here.

Abstract

Neuroimaging and postmortem studies of subjects with major depressive disorder (MDD) reveal smaller hippocampal volume with lengthening duration of illness. Pathology in astrocytes may contribute significantly to this reduced volume and to the involvement of the hippocampus in MDD. Postmortem hippocampal tissues were collected from 17 subjects with MDD and 17 psychiatrically-normal control subjects. Sections from the body of the hippocampus were immunostained for glial fibrillary acidic protein (GFAP), a marker of intermediate filament protein expressed in astrocytes. The density of GFAP-immunoreactive astrocytes was measured in the hippocampus using 3-dimensional cell counting. Hippocampal subfields were also assessed for GFAP-immunoreactive area fraction. In CA1, there was a significant positive correlation between age and either density or area fraction in MDD. The density of astrocytes in the hilus, but not CA1 or CA2/3, was significantly decreased only in depressed subjects not taking an antidepressant drug, but not for depressed subjects taking an antidepressant drug. The area fraction of GFAP-immunoreactivity was significantly decreased in the dentate gyrus in women but not men with depression. In CA2/3, the area fraction of GFAP-immunoreactivity was inversely correlated with the duration of depression in suicide victims. Astrocyte contributions to neuronal function in the hilus may be compromised in depressed subjects not taking antidepressant medication. Due to the cross-sectional nature of the present study of postmortem brain tissue, it remains to be determined whether antidepressant drug treatment prevented a decrease in GFAP-immunoreactive astrocyte density or restored cell density to normal levels.

Citing Articles

Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.

Piatkowska-Chmiel I, Wicha-Komsta K, Pawlowski K, Syrytczyk A, Kocki T, Dudka J Cell Mol Neurobiol. 2025; 45(1):22.

PMID: 40059125 PMC: 11891103. DOI: 10.1007/s10571-025-01534-4.

Proteomics analysis in rats reveals convergent mechanisms between major depressive disorder and dietary zinc deficiency.

Gasior L, Pochwat B, Zareba-Koziol M, Wlodarczyk J, Grabrucker A, Szewczyk B Pharmacol Rep. 2024; 77(1):145-157.

PMID: 39623245 PMC: 11743416. DOI: 10.1007/s43440-024-00681-7.

Reactive Astrocytosis-A Potential Contributor to Increased Suicide in Long COVID-19 Patients?.

Costanza A, Amerio A, Aguglia A, Rossi M, Parise A, Magnani L Brain Sci. 2024; 14(10).

PMID: 39451987 PMC: 11505806. DOI: 10.3390/brainsci14100973.

Omega-3 Polyunsaturated Fatty Acids and Blood-Brain Barrier Integrity in Major Depressive Disorder: Restoring Balance for Neuroinflammation and Neuroprotection.

Zailani H, Wang W, Satyanarayanan S, Chiu W, Liu W, Sung Y Yale J Biol Med. 2024; 97(3):349-363.

PMID: 39351324 PMC: 11426295. DOI: 10.59249/YZLQ4631.

Antidepressant Effects of Ginsenoside Rc on L-Alpha-Aminoadipic Acid-Induced Astrocytic Ablation and Neuroinflammation in Mice.

Kwon D, Kim Y, Cho S Int J Mol Sci. 2024; 25(17).

PMID: 39273621 PMC: 11396248. DOI: 10.3390/ijms25179673.

References

Lu Y, Zeng M, Hu X, Xu H, Swaab D, Ravid R . Estrogen receptor alpha-immunoreactive astrocytes are increased in the hippocampus in Alzheimer's disease. Exp Neurol. 2003; 183(2):482-8. DOI: 10.1016/s0014-4886(03)00205-x. View

Gos T, Schroeter M, Lessel W, Bernstein H, Dobrowolny H, Schiltz K . S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res. 2013; 47(11):1694-9. DOI: 10.1016/j.jpsychires.2013.07.005. View

Khakh B, Sofroniew M . Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015; 18(7):942-52. PMC: 5258184. DOI: 10.1038/nn.4043. View

Kessler R, McGonagle K, Swartz M, Blazer D, Nelson C . Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993; 29(2-3):85-96. DOI: 10.1016/0165-0327(93)90026-g. View

Miguel-Hidalgo J, Rajkowska G . Immunohistochemistry of neural markers for the study of the laminar architecture in celloidin sections from the human cerebral cortex. J Neurosci Methods. 1999; 93(1):69-79. DOI: 10.1016/s0165-0270(99)00114-4. View

Samuels B, Hen R . Neurogenesis and affective disorders. Eur J Neurosci. 2011; 33(6):1152-9. DOI: 10.1111/j.1460-9568.2011.07614.x. View

Rodrigues S, LeDoux J, Sapolsky R . The influence of stress hormones on fear circuitry. Annu Rev Neurosci. 2009; 32:289-313. DOI: 10.1146/annurev.neuro.051508.135620. View

Sheline Y, Wang P, Gado M, Csernansky J, Vannier M . Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996; 93(9):3908-13. PMC: 39458. DOI: 10.1073/pnas.93.9.3908. View

Banasr M, Duman R . Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry. 2008; 64(10):863-70. PMC: 2709733. DOI: 10.1016/j.biopsych.2008.06.008. View

10.

Osterlund M, Hurd Y . Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol. 2001; 64(3):251-67. DOI: 10.1016/s0301-0082(00)00059-9. View

11.

Naninck E, Lucassen P, Bakker J . Sex differences in adolescent depression: do sex hormones determine vulnerability?. J Neuroendocrinol. 2011; 23(5):383-92. DOI: 10.1111/j.1365-2826.2011.02125.x. View

12.

Katzenellenbogen B, Choi I, Delage-Mourroux R, Ediger T, Martini P, Montano M . Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2001; 74(5):279-85. DOI: 10.1016/s0960-0760(00)00104-7. View

13.

Jorgensen P, Edgington N, Schneider B, Rupes I, Tyers M, Futcher B . The size of the nucleus increases as yeast cells grow. Mol Biol Cell. 2007; 18(9):3523-32. PMC: 1951755. DOI: 10.1091/mbc.e06-10-0973. View

14.

Gubba E, Fawcett J, Herbert J . The effects of corticosterone and dehydroepiandrosterone on neurotrophic factor mRNA expression in primary hippocampal and astrocyte cultures. Brain Res Mol Brain Res. 2004; 127(1-2):48-59. DOI: 10.1016/j.molbrainres.2004.05.004. View

15.

Stone D, Song Y, Anderson C, Krohn K, Finch C, Rozovsky I . Bidirectional transcription regulation of glial fibrillary acidic protein by estradiol in vivo and in vitro. Endocrinology. 1998; 139(7):3202-9. DOI: 10.1210/endo.139.7.6084. View

16.

Rajkowska G, Miguel-Hidalgo J, Wei J, Dilley G, Pittman S, Meltzer H . Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999; 45(9):1085-98. DOI: 10.1016/s0006-3223(99)00041-4. View

17.

Bachis A, Mallei A, Cruz M, Wellstein A, Mocchetti I . Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology. 2008; 55(7):1114-20. PMC: 2590765. DOI: 10.1016/j.neuropharm.2008.07.014. View

18.

Chen J, Yao L, Xu B, Qian K, Wang H, Liu Z . Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress. J Huazhong Univ Sci Technolog Med Sci. 2014; 34(6):838-844. DOI: 10.1007/s11596-014-1362-5. View

19.

Little A . Treatment-resistant depression. Am Fam Physician. 2009; 80(2):167-72. View

20.

Zink M, Vollmayr B, Gebicke-Haerter P, Henn F . Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology. 2009; 58(2):465-73. DOI: 10.1016/j.neuropharm.2009.09.005. View